Xeris Biopharma Holdings Announces Global Deal with Beta Bionics

In a strategic move that underscores the company's commitment to innovation within the biopharmaceutical industry, Xeris Biopharma Holdings, Inc. XERS has declared a definitive agreement to collaborate with Beta Bionics on a worldwide scale. The deal will enable both entities to tap into each other's strengths and potentially revolutionize approaches across various medical therapies.

Exclusive Collaboration and Licensing Agreement

The partnership involves an exclusive collaboration and license agreement that has promised to position XERS, a growth-focused biopharma firm, at the forefront of developing pioneering medical products. The companies will work together closely to advance care for patients through cutting-edge solutions that aim to enhance quality of life and streamline drug delivery methods.

About Xeris Pharmaceuticals, Inc.

Xeris Pharmaceuticals, Inc., represented in the stock market by the ticker XERS, is a specialty pharmaceutical company centered in Chicago, Illinois. The firm is renowned for its creation and commercialization of ready-to-use injectable and infusible drug formulations. The recent agreement exemplifies their vision to take patient care to new heights through collaborative ventures and relentless innovation.

Xeris, BetaBionics, Collaboration